Not to be confused with a round-the-clock operation, Twentyeight-Seven Therapeutics Inc. (28-7) managed its time over the past two years by quietly assembling a team of scientific luminaries focused on the task of modulating non-coding RNA (ncRNA) as the platform to discover and develop small molecules that increase levels of the tumor suppressor microRNA (miRNA), Let-7, in cancer indications. Those efforts resonated with a stable of investors, including seed investor MPM Capital, which co-led with Novartis Venture Fund 28-7's $65 million series A. Others in the syndicate included JJDC Inc., Vertex Ventures HC, Longwood Fund, and Astellas Venture Management.